Show cause notices issued to 196 retail medical shops in Telangana

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-11-19 09:48 GMT | Update On 2025-11-19 09:48 GMT

Telangana: In a sweeping statewide crackdown, the Drugs Control Administration, Telangana, has issued show cause notices to 196 retail medical shops after inspections revealed various discrepancies.

The inspections were carried out on 17 November 2025 as part of a special drive to detect irregularities in retail medical shops across the state.

The special drive was conducted with prime emphasis on verifying the sale of Schedule H1 drugs, including higher-generation antibiotics and habit-forming drugs, and ensuring that retail medical shops dispense them only against a valid prescription issued by a Registered Medical Practitioner.

The inspections also emphasized the proper maintenance of registers, dispensing of prescription drugs under the supervision of a Registered Pharmacist, and verification of the sale of medicines by retail pharmacies in accordance with the revised GST slabs.

During the special drive, officers of the Drugs Control Administration detected several violations in 196 retail medical shops. The irregularities reported included the dispensing of Schedule H1 medicines without a valid prescription issued by a Registered Medical Practitioner; sale of prescription medicines in the absence of a Registered Pharmacist; non-maintenance or failure to produce Schedule H1 drug registers, sales bills, and purchase bills for medicines stocked in the retail medical shops; irregularities in maintaining copies of sales and purchase bills; and other related violations.

Show Cause Notices were issued to all 196 retail medical shops for the violations reported, and action shall be taken as per the provisions of the Drugs and Cosmetics Act, 1940, and the Rules made thereunder.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Show cause notices issued to 196 retail medical shops in Telangana

Similar News

Syngene International appoints Dr Rohtash Kumar as Head of CDMO, Small and Large Molecule

Solara Active Pharma Sciences Mangalore facility successfully completes USFDA inspection

USFDA approves Marksans Pharma anti-diarrheal medication

Biocon Pharma gets USFDA nod for arthritis drug Tofacitinib ER

People Must Get a Proper Remedy: SC Criticizes Pharma Marketing Code Gaps

High-Level Ethiopia Delegation Meets DCGI, IPC to Strengthen Pharmaceutical Ties

Dr Ajay Sharma to resign as Director - Corporate Affairs of AstraZeneca Pharma India